Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2024 13:10 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a...
May 30, 2024 16:45 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Departure of Chief Financial Officer

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
May 21, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 20, 2024 17:45 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

SAB Biotherapeutics Announces Q1 2024 Financial Results
May 06, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
April 16, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Provides SAB-142 Trial Update

SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes
April 08, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics to Present at INNODIA Annual Meeting

SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA.
April 04, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that...
March 29, 2024 07:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release...
March 25, 2024 10:15 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...